目的 探討大蒜素注射液聯(lián)合伏立康唑治療肺部真菌感染的臨床效果。方法 選取西安交通大學(xué)第二附屬醫(yī)院2016年5月—2017年10月收治的肺部真菌感染患者116例，隨機(jī)分成對照組合和治療組，每組各58例。對照組第1天靜脈注射注射用伏立康唑，400 mg/次，第2天減至200 mg/次，2次/d，待患者體溫恢復(fù)正常、肺部病灶明顯吸收、癥狀消失或明顯好轉(zhuǎn)后，改為口服伏立康唑片，200 mg/次，2次/d。治療組在對照組基礎(chǔ)上靜脈滴注大蒜素注射液，60 mg加入5%葡萄糖注射液250 mL，再加入50 mg利多卡因注射液，1次/d。兩組均治療14 d。觀察兩組患者臨床療效，同時(shí)比較治療前后兩組患者真菌感染清除率和生命體征變化。結(jié)果 治療后，對照組臨床有效率為75.86%，顯著低于治療組的94.83%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，對照組真菌感染清除率為72.41%，明顯低于治療組的91.38%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組體溫、呼吸頻率、脈搏頻率、收縮壓、舒張壓均明顯降低（P<0.05），且治療組患者生命體征明顯低于對照組（P<0.05）。結(jié)論 大蒜素注射液聯(lián)合伏立康唑治療肺部真菌感染能有效改善臨床癥狀體征，提高臨床療效，且不良反應(yīng)輕微。

Objective To investigate the clinical effect of Allitride Injection combined with voriconazole in treatment of pulmonary fungal infection. Methods Patients (116 cases) with pulmonary fungal infection in the Second Affiliated Hospital of Xi'an Jiaotong University from May 2016 to October 2017 were randomly divided into control and treatment groups, and each group had 58 cases. Patients in the control group were iv administered with Voriconazole for injection for the first day, 400 mg/time, and reduced to 200 mg/time from 2nd day, twice daily, they were po administered with Voriconazole Tablets after temperature returned to normal, absorption of pulmonary lesions, symptoms disappeared or improved markedly, 200 mg/time, twice daily. Patients in the treatment group were iv administered with Allitride Injection on the basis of the control group, 60 mg added into 5% glucose injection 250 mL, and 50 mg lidocaine was also added, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the clearance rate of fungal infection, the change of vital signs in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 75.86%, which was significantly lower than 94.83% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the clearance rate of fungal infection in the control group was 72.41%, which was significantly lower than 91.38% in the treatment group, and there were differences between two groups (P<0.05). After treatment, temperature, breathing frequency, pulse frequency, systolic and diastolic blood pressure in two groups was significantly decreased (P<0.05), and the vital signs in the treatment group were significantly lower than that in the control group (P<0.05). Conclusion Allitride Injection combined with voriconazole in treatment of pulmonary fungal infection can effectively promote clinical symptoms and signs, improve clinical efficacy, and has slight adverse reactions.